OBRR Lab

The contract opportunity involves the development of a prophylactic vaccine targeting visceral leishmaniasis, a severe parasitic disease. It is listed under the Food and Drug Administration (FDA) with the solicitation titled "OBRR Lab" and categorized in the NAICS code 423450, which pertains to medical and pharmaceutical wholesalers. This forecasted contract aims to support innovative efforts in preventing this serious health threat, although specific location details for performance and award are not provided. The FDA is the overseeing agency, with program and acquisition management points of contact designated to facilitate communication, including a CBER Acquisition Liaison accessible via email. The contracting officer has not yet been named. Given the nature of the solicitation as a forecast, it signals a prospective opportunity rather than an active solicitation, allowing interested parties to prepare for potential upcoming contract actions related to vaccine development efforts under the FDA’s purview.